Smart delivery systems in various development stages from preclinical to early clinical trials, including closed-loop insulin pumps and glucose-responsive insulin formulations, are being developed to provide automated, physiologic insulin delivery that minimizes hypoglycemia risk and reduces the need of additional glucose monitoring (84, 85). The gene discussed is INS; the disease is Hypoglycemia.